 RedHill Biopharma Ltd. has announced the results of a new preclinical study with its oral pill drug candidate opaganib ABC294640, demonstrating its efficacy in significantly decreasing renal fibrosis in a unilateral ureteral obstruction-induced renal interstitial fibrosis model. 